Trastuzumab Cardiotoxicity: Mechanism and Management

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Trastuzumab is a widely used breast cancer therapy.
• It carries a risk of cardiotoxicity, including arrhythmia, cardiomyopathy, and heart failure.
• Mechanisms of trastuzumab-induced cardiotoxicity are being elucidated, potentially involving the erythroblastic oncogene B2 receptor.

Purpose of the Study:

• To review the mechanisms, diagnostic approaches, and therapeutic/preventive strategies for cardiotoxicity associated with anti-human epidermal growth factor receptor 2 therapies.
• To provide a comprehensive overview of managing cardiac adverse effects of trastuzumab.

Main Methods:

• Review of existing literature on trastuzumab cardiotoxicity.
• Discussion of diagnostic tools such as echocardiography, cardiac biomarkers (troponin I, NT-proBNP), and MRI.
• Analysis of current and emerging pharmacological interventions.

Main Results:

• Cardiotoxicity is a significant concern with trastuzumab therapy.
• Early diagnosis is possible through cardiac function assessment and biomarkers.
• Established heart failure treatments (e.g., beta-blockers, ACE inhibitors) and newer agents (e.g., ARNIs, SGLT2 inhibitors) show promise.
• PCSK9 inhibitors are also being investigated for cardioprotective effects.

Conclusions:

• Effective management of trastuzumab cardiotoxicity requires a multi-faceted approach.
• Monitoring cardiac function and utilizing appropriate diagnostic tools are essential.
• Pharmacological interventions, including established and novel therapies, are key to preventing and treating cardiac adverse events.